Is NCT06915753 recruiting in San Francisco, CA?

Yes, NCT06915753 is currently recruiting participants at its San Francisco, CA location. This metastatic hepatocellular carcinoma clinical trial is actively enrolling qualified participants.

Is participation in this San Francisco clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Metastatic Hepatocellular Carcinoma Clinical Trial in San Francisco, CA

Q: How do I join the metastatic hepatocellular carcinoma clinical trial in San Francisco?

To join this clinical trial in San Francisco, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

About This Metastatic Hepatocellular Carcinoma Study in San Francisco

A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

Sponsor: Tyra Biosciences, Inc

Who Can Participate

Inclusion Criteria

All Patients:

Age ≥ 18 years

Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.

Adequate end organ function.

Ability to swallow oral formulations.

Ability to understand and willingness to sign the ICF. Part A:

Histologically confirmed locally advanced unresectable/metastatic HCC or histologically confirmed advanced solid tumor with documented FGF/FGFR pathway alterations

For participants with histologically confirmed locally advanced or metastatic HCC:

Barcelona Clinic Liver Cancer (BCLC) stage B that is not eligible for locoregional therapy, or stage C.

Child-Pugh Score class A

Must have previously received SOC appropriate for their tumor type. Any number of prior therapies, including FGFR inhibitors, are permitted.

Agree to provide archival tumor tissue no older than 2 years from the time of enrollment, if available. If an archived specimen is not available, a biopsy is not required. Part B, Cohort 1:

Histologically confirmed locally advanced/metastatic HCC who have previously received standard of care.

Barcelona Clinic Liver Cancer (BCLC) stage B that is not eligible for locoregional therapy, or stage C.

Child-Pugh Score class A

Availability of an archival formalin-fixed paraffin-embedded (FFPE) tumor tissue specimen obtained ≤2 years prior to screening for submission to sponsor-designated central laboratory for FGF19 IHC testing.

At least 1 measurable lesion by RECIST v1.1. Part B, Cohort 2:

Histologically confirmed advanced solid tumor except FGFR3-altered urothelial carcinoma and primary central nervous system tumors who have previously received standard of care. Note: Participants with confirmed diagnosis of locally advanced or metastatic HCC are not eligible for Cohort 2.

Must have an eligible activating gain-of-function alteration in the FGFR3 or FGFR4 gene, or focal amplifications of FGF19

Archival tumor tissue biopsy specimen no older than 2 years from the time of enrollment, if available. If a tissue biopsy specimen is not available, a biopsy is not required.

At least 1 measurable lesion by RECIST v1.1. Key

Exclusion Criteria

All Patients:

Have disease that is suitable for local therapy administered with curative intent.

Have not recovered from reversible toxicity of prior anticancer therapy to \< Grade 1 or baseline (except toxicities that are not clinically significant or not expected to resolve, including but not limited to, alopecia, fatigue, skin discoloration, or Grade 1 neuropathy).

Have received the following anticancer therapy:

Any immunotherapy or other antibody therapy within 28 days prior to the first dose of the study drug.

A TKI \< 5 days or 5X the terminal Phase elimination half-lives, whichever is longer, prior to the first dose of TYRA-430.

Other systemic therapy not listed above \< 14 days prior to the first dose of the study drug.

Participant discontinued a prior anti-FGFR therapy due to significant toxicity, defined as hepatotoxicity ≥ Grade 3 or any Grade 4 toxicity according to CTCAE v5.0.

Has a serum phosphorus level \> upper limit of normal (ULN) during screening that remains \>ULN despite medical management.

History of or current uncontrolled cardiovascular disease.

Active, symptomatic, or untreated brain metastases.

Have a diagnosis of primary CNS malignancies.

Gastrointestinal disorders that will affect oral administration or absorption of TYRA-430.

Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.

Any reason that, in the view of investigator, would substantially impair the ability of the participant to comply with study procedures and increase the risk to the participant. Part B, Cohort 1:

Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.

Prior treatment with pan-FGFR inhibitors or FGFR4-selective inhibitors. Part B, Cohort 2:

Histologically confirmed locally advanced/metastatic HCC.

Histologically confirmed urothelial cancer.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT06915753) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Hepatocellular Carcinoma Treatment Options in San Francisco, CA

If you're searching for metastatic hepatocellular carcinoma treatment options in San Francisco, CA, this clinical trial (NCT06915753) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic hepatocellular carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic hepatocellular carcinoma clinical trials near you to find additional studies recruiting in your area.

Metastatic Hepatocellular Carcinoma Clinical Trial in San Francisco, CA

Expert Care in San Francisco

IRB Approved

No-Cost Care

Apply for This San Francisco Location

Why Participate?

Simple Process